Symbols / SYRS
SYRS Chart
About
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 5.37K |
| Enterprise Value | 1.96M | Income | -97.81M | Sales | 386.00K |
| Book/sh | -0.41 | Cash/sh | 2.17 | Dividend Yield | — |
| Payout | 0.00% | Employees | 68 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | 0.01 | P/B | -0.00 | P/C | — |
| EV/EBITDA | -0.02 | EV/Sales | 5.07 | Quick Ratio | 2.05 |
| Current Ratio | 2.25 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -3.07 | EPS next Y | -2.61 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-10-31 06:00 | ROA | -59.88% |
| ROE | -7.77% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -288.92% | Profit Margin | 0.00% | Shs Outstand | 26.83M |
| Shs Float | 26.71M | Short Float | 3.81% | Short Ratio | 0.80 |
| Short Interest | — | 52W High | 0.30 | 52W Low | 0.00 |
| Beta | 1.15 | Avg Volume | 34.75K | Volume | 904.00 |
| Target Price | $8.75 | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.75
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-38.87
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
$4.00
High
$20.00
Mean
$8.75
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-11-13 | down | TD Cowen | Buy → Hold | — |
| 2024-11-13 | down | HC Wainwright & Co. | Buy → Neutral | $1 |
| 2024-11-13 | down | JMP Securities | Market Outperform → Market Perform | — |
| 2024-11-13 | down | Brookline Capital | Buy → Hold | — |
| 2024-11-01 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-08-13 | reit | Piper Sandler | Overweight → Overweight | $5 |
| 2024-08-13 | main | JMP Securities | Market Outperform → Market Outperform | $4 |
| 2024-08-13 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-06-26 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-04-03 | reit | Piper Sandler | Overweight → Overweight | $13 |
| 2024-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-10-03 | main | Piper Sandler | Overweight → Overweight | $7 |
| 2023-08-09 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-05-11 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-05-11 | main | JMP Securities | Market Outperform → Market Outperform | $15 |
| 2023-03-03 | main | Oppenheimer | — → Outperform | $13 |
| 2023-03-03 | reit | HC Wainwright & Co. | — → Buy | $15 |
| 2023-01-05 | main | Piper Sandler | — → Overweight | $20 |
- SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Nasdaq Fri, 30 May 2025 07
- Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus ue, 15 Apr 2025 07
- Failed Clinical Trial Forces Syros Pharmaceuticals Into Delisting and Wind-Down Operations - Stock Titan Fri, 28 Feb 2025 08
- Why Is Syros Pharmaceuticals (SYRS) Stock Down 62% Today? - InvestorPlace ue, 13 Aug 2024 07
- Syros Pharmaceuticals stock plunges to 52-week low of $0.16 - Investing.com ue, 25 Feb 2025 08
- Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - Yahoo Finance hu, 14 Nov 2024 08
- Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why - Nasdaq Fri, 19 Jan 2024 08
- Syros Pharmaceuticals Stock (NASDAQ:SYRS): Worse than a Powerball Lottery Ticket? - TipRanks Mon, 07 Nov 2022 08
- Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis $SYRS - MarketBeat Mon, 15 Aug 2016 12
- Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS) - Yahoo Finance hu, 12 Sep 2024 07
- Shareholders in Syros Pharmaceuticals (NASDAQ:SYRS) have lost 77%, as stock drops 13% this past week - simplywall.st hu, 16 Dec 2021 08
- SYRS - Syros Pharmaceut Latest Stock News & Market Updates - Stock Titan Sun, 11 Oct 2020 10
- Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com Wed, 08 Jan 2025 08
- Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday - InvestorPlace ue, 13 Aug 2024 07
- Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination - Nasdaq Wed, 14 Aug 2024 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 37070 | 10016.0 | — | Sale at price 0.27 per share. | SIMONIAN NANCY A | Director | — | 2024-12-02 00:00:00 | D |
| 1 | 134713 | 35739.0 | — | Sale at price 0.27 per share. | SIMONIAN NANCY A | Director | — | 2024-11-25 00:00:00 | D |
| 2 | 46657 | 12915.0 | — | Sale at price 0.28 per share. | QUIRK GERALD E. | Officer | — | 2024-11-19 00:00:00 | D |
| 3 | 12099 | 2382.0 | — | Sale at price 0.20 per share. | ROTH DAVID A M.D. | Officer | — | 2024-11-18 00:00:00 | D |
| 4 | 36133 | 7949.0 | — | Sale at price 0.22 per share. | STEPHENS KRISTIN | Officer | — | 2024-11-18 00:00:00 | D |
| 5 | 134797 | 26932.0 | — | Sale at price 0.20 per share. | CHEE CONLEY | Chief Executive Officer | — | 2024-11-18 00:00:00 | D |
| 6 | 137803 | 28980.0 | — | Sale at price 0.21 per share. | HAAS JASON | Chief Financial Officer | — | 2024-11-18 00:00:00 | D |
| 7 | 40125 | nan | — | — | SIMONIAN NANCY A | Director | — | 2024-10-31 00:00:00 | D |
| 8 | 18875 | nan | — | — | ROTH DAVID A M.D. | Officer | — | 2024-10-31 00:00:00 | D |
| 9 | 17000 | nan | — | — | STEPHENS KRISTIN | Officer | — | 2024-10-31 00:00:00 | D |
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -117.43M | -121.53M | -96.31M |
| TotalUnusualItems | -39.76M | 33.71M | 16.68M |
| TotalUnusualItemsExcludingGoodwill | -39.76M | 33.71M | 16.68M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -164.57M | -94.65M | -86.56M |
| ReconciledDepreciation | 2.25M | 2.71M | 3.02M |
| EBITDA | -157.19M | -87.81M | -79.63M |
| EBIT | -159.45M | -90.52M | -82.65M |
| NetInterestIncome | 1.69M | -2.00M | -3.82M |
| InterestExpense | 5.13M | 4.13M | 3.91M |
| InterestIncome | 6.82M | 2.13M | 87.00K |
| NormalizedIncome | -124.81M | -128.37M | -103.24M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -164.57M | -94.65M | -86.56M |
| TotalExpenses | 136.44M | 141.24M | 122.91M |
| TotalOperatingIncomeAsReported | -128.99M | -135.87M | -99.42M |
| DilutedAverageShares | 28.33M | 12.63M | 6.25M |
| BasicAverageShares | 28.33M | 12.63M | 6.25M |
| DilutedEPS | -5.81 | -7.49 | -13.84 |
| BasicEPS | -5.81 | -7.49 | -13.84 |
| DilutedNIAvailtoComStockholders | -164.57M | -94.65M | -86.56M |
| NetIncomeCommonStockholders | -164.57M | -94.65M | -86.56M |
| NetIncome | -164.57M | -94.65M | -86.56M |
| NetIncomeIncludingNoncontrollingInterests | -164.57M | -94.65M | -86.56M |
| NetIncomeContinuousOperations | -164.57M | -94.65M | -86.56M |
| PretaxIncome | -164.57M | -94.65M | -86.56M |
| OtherIncomeExpense | -39.76M | 33.71M | 16.68M |
| OtherNonOperatingIncomeExpenses | -9.51M | ||
| SpecialIncomeCharges | -2.49M | -9.51M | 0.00 |
| RestructuringAndMergernAcquisition | 2.49M | 9.51M | 0.00 |
| GainOnSaleOfSecurity | -37.27M | 43.22M | 16.68M |
| NetNonOperatingInterestIncomeExpense | 1.69M | -2.00M | -3.82M |
| InterestExpenseNonOperating | 5.13M | 4.13M | 3.91M |
| InterestIncomeNonOperating | 6.82M | 2.13M | 87.00K |
| OperatingIncome | -126.50M | -126.36M | -99.42M |
| OperatingExpense | 136.44M | 141.24M | 122.91M |
| ResearchAndDevelopment | 108.15M | 111.94M | 99.87M |
| SellingGeneralAndAdministration | 28.28M | 29.30M | 23.04M |
| GeneralAndAdministrativeExpense | 28.28M | 29.30M | 23.04M |
| OtherGandA | 28.28M | 29.30M | 23.04M |
| TotalRevenue | 9.94M | 14.88M | 23.49M |
| OperatingRevenue | 9.94M | 14.88M | 23.49M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 26.45M | 20.26M | 6.20M |
| ShareIssued | 26.45M | 20.26M | 6.20M |
| TotalDebt | 62.08M | 63.57M | 65.19M |
| TangibleBookValue | 16.66M | 127.74M | 85.22M |
| InvestedCapital | 57.88M | 168.38M | 125.47M |
| WorkingCapital | 108.30M | 180.61M | 105.08M |
| NetTangibleAssets | 16.66M | 127.74M | 85.22M |
| CapitalLeaseObligations | 20.85M | 22.92M | 24.93M |
| CommonStockEquity | 16.66M | 127.74M | 85.22M |
| TotalCapitalization | 51.22M | 168.38M | 125.47M |
| TotalEquityGrossMinorityInterest | 16.66M | 127.74M | 85.22M |
| StockholdersEquity | 16.66M | 127.74M | 85.22M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 102.00K | -79.00K |
| OtherEquityAdjustments | 102.00K | -79.00K | |
| RetainedEarnings | -722.81M | -558.23M | -463.58M |
| AdditionalPaidInCapital | 739.44M | 685.85M | 548.87M |
| CapitalStock | 26.00K | 20.00K | 6.00K |
| CommonStock | 26.00K | 20.00K | 6.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 151.51M | 116.75M | 97.72M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 114.83M | 85.97M | 66.21M |
| OtherNonCurrentLiabilities | 61.75M | 24.47M | 3.03M |
| DerivativeProductLiabilities | 61.75M | 24.47M | 3.03M |
| NonCurrentDeferredLiabilities | 0.00 | ||
| NonCurrentDeferredRevenue | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 53.08M | 61.50M | 63.18M |
| LongTermCapitalLeaseObligation | 18.53M | 20.85M | 22.92M |
| LongTermDebt | 34.56M | 40.65M | 40.26M |
| CurrentLiabilities | 36.68M | 30.78M | 31.51M |
| CurrentDeferredLiabilities | 0.00 | 4.33M | 10.18M |
| CurrentDeferredRevenue | 0.00 | 4.33M | 10.18M |
| CurrentDebtAndCapitalLeaseObligation | 8.99M | 2.07M | 2.01M |
| CurrentCapitalLeaseObligation | 2.32M | 2.07M | 2.01M |
| CurrentDebt | 6.67M | ||
| OtherCurrentBorrowings | 6.67M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 6.99M | 8.53M | 6.34M |
| PayablesAndAccruedExpenses | 20.70M | 15.85M | 12.97M |
| CurrentAccruedExpenses | 9.15M | 9.44M | 9.28M |
| Payables | 11.54M | 6.41M | 3.69M |
| AccountsPayable | 11.54M | 6.41M | 3.69M |
| TotalAssets | 168.17M | 244.49M | 182.94M |
| TotalNonCurrentAssets | 23.19M | 33.09M | 46.35M |
| OtherNonCurrentAssets | 3.71M | 8.43M | 6.03M |
| InvestmentsAndAdvances | 0.00 | 13.04M | |
| InvestmentinFinancialAssets | 0.00 | 13.04M | |
| AvailableForSaleSecurities | 13.04M | ||
| NetPPE | 19.48M | 24.66M | 27.29M |
| AccumulatedDepreciation | -7.63M | -12.55M | -9.86M |
| GrossPPE | 27.12M | 37.22M | 37.14M |
| Leases | 11.66M | 11.66M | 11.66M |
| ConstructionInProgress | 0.00 | ||
| OtherProperties | 12.19M | 22.45M | 22.43M |
| MachineryFurnitureEquipment | 3.27M | 3.11M | 3.05M |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 144.98M | 211.39M | 136.59M |
| OtherCurrentAssets | 5.45M | 7.39M | 3.24M |
| PrepaidAssets | 3.24M | ||
| Receivables | 0.00 | 1.69M | 2.98M |
| OtherReceivables | 1.69M | 2.98M | |
| AccountsReceivable | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 139.53M | 202.30M | 130.37M |
| OtherShortTermInvestments | 0.00 | 34.84M | 38.07M |
| CashAndCashEquivalents | 139.53M | 167.47M | 92.30M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -109.98M | -124.31M | -100.78M |
| RepurchaseOfCapitalStock | 0.00 | -81.00K | |
| RepaymentOfDebt | -65.00K | -291.00K | -265.00K |
| IssuanceOfDebt | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 43.27M | 119.76M | 70.34M |
| CapitalExpenditure | -272.00K | -1.24M | -1.25M |
| InterestPaidSupplementalData | 4.55M | 3.41M | 3.19M |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 141.65M | 170.55M | 95.39M |
| BeginningCashPosition | 170.55M | 95.39M | 177.07M |
| ChangesInCash | -28.91M | 75.17M | -81.68M |
| FinancingCashFlow | 43.46M | 131.04M | 70.51M |
| CashFlowFromContinuingFinancingActivities | 43.46M | 131.04M | 70.51M |
| NetOtherFinancingCharges | 11.44M | -41.00K | |
| ProceedsFromStockOptionExercised | 257.00K | 218.00K | 480.00K |
| NetPreferredStockIssuance | 0.00 | ||
| PreferredStockIssuance | 0.00 | ||
| NetCommonStockIssuance | 43.27M | 119.68M | 70.34M |
| CommonStockPayments | 0.00 | -81.00K | |
| CommonStockIssuance | 43.27M | 119.76M | 70.34M |
| NetIssuancePaymentsOfDebt | -65.00K | -291.00K | -265.00K |
| NetLongTermDebtIssuance | -65.00K | -291.00K | -265.00K |
| LongTermDebtPayments | -65.00K | -291.00K | -265.00K |
| LongTermDebtIssuance | 0.00 | 0.00 | |
| InvestingCashFlow | 37.34M | 67.19M | -52.65M |
| CashFlowFromContinuingInvestingActivities | 37.34M | 67.19M | -52.65M |
| NetInvestmentPurchaseAndSale | 36.05M | 68.43M | -51.41M |
| SaleOfInvestment | 87.02M | 68.43M | 0.00 |
| PurchaseOfInvestment | -50.97M | 0.00 | -51.41M |
| NetPPEPurchaseAndSale | 1.29M | -1.24M | -1.25M |
| SaleOfPPE | 1.56M | 0.00 | 0.00 |
| PurchaseOfPPE | -272.00K | -1.24M | -1.25M |
| OperatingCashFlow | -109.71M | -123.06M | -99.54M |
| CashFlowFromContinuingOperatingActivities | -109.71M | -123.06M | -99.54M |
| ChangeInWorkingCapital | 5.05M | -5.52M | -10.60M |
| ChangeInOtherWorkingCapital | -4.33M | -5.85M | -12.64M |
| ChangeInOtherCurrentLiabilities | -959.00K | -848.00K | |
| ChangeInOtherCurrentAssets | 3.76M | -2.41M | -1.20M |
| ChangeInPayablesAndAccruedExpense | 2.95M | 5.11M | 4.88M |
| ChangeInAccruedExpense | -2.18M | 2.35M | 4.83M |
| ChangeInPayable | 5.13M | 2.77M | 48.00K |
| ChangeInAccountPayable | 5.13M | 2.77M | 48.00K |
| ChangeInPrepaidAssets | 1.94M | -2.81M | -995.00K |
| ChangeInReceivables | 1.69M | 1.28M | -648.00K |
| ChangesInAccountReceivables | 0.00 | 7.00K | |
| OtherNonCashItems | 650.00K | 953.00K | 706.00K |
| StockBasedCompensation | 10.43M | 11.41M | 10.35M |
| AssetImpairmentCharge | 515.00K | 0.00 | |
| AmortizationOfSecurities | -1.31M | 243.00K | 224.00K |
| DepreciationAmortizationDepletion | 2.25M | 2.71M | 3.02M |
| DepreciationAndAmortization | 2.25M | 2.71M | 3.02M |
| Depreciation | 2.97M | 3.02M | |
| OperatingGainsLosses | 37.27M | -38.21M | -16.68M |
| GainLossOnInvestmentSecurities | 37.27M | -38.21M | -16.68M |
| GainLossOnSaleOfPPE | 0.00 | ||
| NetIncomeFromContinuingOperations | -164.57M | -94.65M | -86.56M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for SYRS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|